Oksetatte

Oksetatte, also known as oksetamin, is a dissociative anesthetic drug that was developed in the 1960s. It is a derivative of ketamine, with the addition of an oxetane ring in its structure. Oksetatte was initially marketed as a sedative and analgesic, but its use has since been largely discontinued due to its potential for abuse and the development of safer alternatives.

Oksetatte acts on the brain by binding to the NMDA receptor, a type of glutamate receptor involved in synaptic plasticity and pain modulation. This binding leads to a dissociative state, characterized by altered perception of reality, detachment from the environment, and a sense of detachment from one's own body. These effects are similar to those produced by ketamine, but oksetatte has a longer duration of action.

The use of oksetatte has been associated with several adverse effects, including hallucinations, delusions, and cognitive impairment. It has also been linked to an increased risk of suicidal behavior, particularly in young adults. Due to these risks, oksetatte was withdrawn from the market in many countries in the 1980s and 1990s.

Despite its discontinuation, oksetatte remains a subject of interest for researchers studying the mechanisms of action of dissociative anesthetics and the treatment of mental health conditions. Its unique pharmacological profile and long duration of action make it a valuable tool for studying the NMDA receptor and its role in the brain. However, its potential for abuse and the associated risks make it a drug that should be used with extreme caution, if at all.